0001209191-20-037560.txt : 20200618
0001209191-20-037560.hdr.sgml : 20200618
20200618161044
ACCESSION NUMBER: 0001209191-20-037560
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200616
FILED AS OF DATE: 20200618
DATE AS OF CHANGE: 20200618
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Freed Martin I
CENTRAL INDEX KEY: 0001676653
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38360
FILM NUMBER: 20972622
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGEPARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Solid Biosciences Inc.
CENTRAL INDEX KEY: 0001707502
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 900943402
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 141 PORTLAND STREET, FIFTH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-337-4680
MAIL ADDRESS:
STREET 1: 141 PORTLAND STREET, FIFTH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Solid Biosciences, LLC
DATE OF NAME CHANGE: 20170524
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-16
0
0001707502
Solid Biosciences Inc.
SLDB
0001676653
Freed Martin I
C/O SOLID BIOSCIENCES INC.
141 PORTLAND STREET, 5TH FLOOR
CAMBRIDGE
MA
02139
1
0
0
0
Director Stock Option (Right to Buy)
3.03
2020-06-16
4
A
0
30000
0.00
A
2030-06-16
Common Stock
30000
30000
D
Director Stock Option (Right to Buy)
3.03
2020-06-16
4
A
0
10000
0.00
A
2030-06-16
Common Stock
10000
10000
D
This option was granted on June 16, 2020 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
This option was granted on June 16, 2020 to members of the Clinical Committee of the Board of Directors and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
/s/ by Lynette Herscha as attorney-in-fact for Martin Freed
2020-06-18